Johnson & Johnson (JNJ)

140.47
NYSE : Health Technology
Prev Close 140.47
Day Low/High 0.00 / 0.00
52 Wk Low/High 118.62 / 148.32
Avg Volume 6.06M
Exchange NYSE
Shares Outstanding 2.68B
Market Cap 383.31B
EPS 0.50
P/E Ratio 274.77
Div & Yield 3.60 (2.45%)

Latest News

Janssen Announces Results Of Esketamine Nasal Spray Phase 3 Study In Patients With Treatment-Resistant Depression

Janssen Announces Results Of Esketamine Nasal Spray Phase 3 Study In Patients With Treatment-Resistant Depression

Study is one of five submitted to U.S. FDA by Janssen as part of its new drug application for esketamine nasal spray for treatment-resistant depression

Weekly Roundup

U.S. equity markets pushed to record highs this week despite increased trade tensions.

Jim's Daily Rundown

Jim discusses what to look to buy when the market is at all-time highs, Disney and Comcast, Salesforce.com, Raytheon, and more!

NAACP Chief Johnson Touts Merits of Diversity, New ETF

NAACP Chief Johnson Touts Merits of Diversity, New ETF

Derrick Johnson talks to TheStreet about diversity across corporate America.

Jim's Daily Rundown

Jim discusses a wide range of stocks and stock related issues.

Jim's Daily Rundown

Jim covers a variety of stocks today, including the club's newest position in JNJ.

Initiating Position in Johnson & Johnson

We welcome this opportunity to buy a stable, long-term holding at an attractive price.

Ignore the Misleading Dow Jones Industrial Average

Ignore the Misleading Dow Jones Industrial Average

The DJIA is not accurately reflecting what's going on in the market and will cause you to miss broader weakness that has taken hold.

Janssen Submits Esketamine Nasal Spray New Drug Application To U.S. FDA For Treatment-Resistant Depression

Janssen Submits Esketamine Nasal Spray New Drug Application To U.S. FDA For Treatment-Resistant Depression

If approved, esketamine nasal spray would provide the first new mechanism of action in 30 years to treat this debilitating mental illness1,2

3 Things That Could Send the Market Spiraling

3 Things That Could Send the Market Spiraling

Here are some real reasons to be bearish stocks just as they hover around record highs.

New Rules for This Market: Cramer's 'Mad Money' Recap (Tues. 8/28/18)

New Rules for This Market: Cramer's 'Mad Money' Recap (Tues. 8/28/18)

Jim Cramer's new rules of the road will help investors stay on course and avoid common mistakes.

Johnson & Johnson Becomes #15 Most Shorted Dow Stock, Replacing MMM

Johnson & Johnson Becomes #15 Most Shorted Dow Stock, Replacing MMM

The most recent short interest data has been released for the 08/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Caldwell Cassady & Curry Helps Acantha Win $8.2 Million Patent Infringement Verdict Against Medical Device Giant DePuy Synthes

Caldwell Cassady & Curry Helps Acantha Win $8.2 Million Patent Infringement Verdict Against Medical Device Giant DePuy Synthes

Wisconsin jurors find that DePuy Synthes infringed orthopedic implant patent

Don't Forget the Consumer: Cramer's 'Mad Money' Recap (Wednesday 8/22/18)

Don't Forget the Consumer: Cramer's 'Mad Money' Recap (Wednesday 8/22/18)

Jim Cramer says we have a $19 trillion economy, and two-thirds of it is based on consumer spending -- not manufacturing, or sales, or industry.

Drug Companies Start Keeping Prices in Check to Avoid Government Crackdown

Drug Companies Start Keeping Prices in Check to Avoid Government Crackdown

The industry has taken to smaller, voluntary measures to avoid serious federal action on pricing.

Global Consumer Is the Hero of the Longest Bull Market

Global Consumer Is the Hero of the Longest Bull Market

The heroes of the bull market aren't politicians or businessmen or even Fed chairmen: it's U.S. and global consumers.

Jim Cramer: What Does Politics Have to Do With Johnson & Johnson's P/E?

Jim Cramer: What Does Politics Have to Do With Johnson & Johnson's P/E?

The answer is plenty, but you can't trade that.

J&J Stock Is Firming Up Nicely, Stay Long

J&J Stock Is Firming Up Nicely, Stay Long

Let's check some updated charts to see if our strategy is still on track.

Jim Cramer: This Is a Rotation, Not a Recession

Jim Cramer: This Is a Rotation, Not a Recession

There's too much evidence of economic strength, so don't interpret these moves as a sign of a real slowdown.

Why Pay a Premium for Estee Lauder?

Why Pay a Premium for Estee Lauder?

EL's stock is up despite a guidance cut.

Investors May Have Omarosa to Thank for Pretty Good Week

Investors May Have Omarosa to Thank for Pretty Good Week

Thanks, Omarosa. And you too, Bob Mueller, for distracting the president this week from trade wars and tariff skirmishes and allowing investors to make some money.

JetBlue, Southwest, Johnson & Johnson: 'Mad Money' Lightning Round

JetBlue, Southwest, Johnson & Johnson: 'Mad Money' Lightning Round

Jim Cramer takes a look at JetBlue, Southwest, Johnson & Johnson, Aspen Technology, Stratasys, Laredo Petroleum, Lumber Liquidators, and more.

Worried About the Right Thing?: Cramer's 'Mad Money' Recap (Tuesday 8/14/18)

Worried About the Right Thing?: Cramer's 'Mad Money' Recap (Tuesday 8/14/18)

Jim Cramer says some people are worried about tariffs and Turkey, but he's more concerned about spending patterns at home.

TheStreet Quant Rating: B (Buy)